Fortrea Holdings (FRA:K67) Short-Term Debt : €51 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Short-Term Debt?

Fortrea Holdings's Short-Term Debt for the quarter that ended in Mar. 2024 was €51 Mil.

Fortrea Holdings's quarterly Short-Term Debt declined from Sep. 2023 (€24 Mil) to Dec. 2023 (€24 Mil) but then increased from Dec. 2023 (€24 Mil) to Mar. 2024 (€51 Mil).

Fortrea Holdings's annual Short-Term Debt stayed the same from Dec. 2021 (€0 Mil) to Dec. 2022 (€0 Mil) but then increased from Dec. 2022 (€0 Mil) to Dec. 2023 (€24 Mil).

Fortrea Holdings Short-Term Debt Historical Data

The historical data trend for Fortrea Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Short-Term Debt Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

23.93

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial						-	24.09	24.46	23.93	50.60

Fortrea Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Fortrea Holdings Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings (FRA:K67) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

FTRE:USA

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings (FRA:K67) Headlines

No Headlines